Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 60.7% in April

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 2,682 shares, a decrease of 60.7% from the April 15th total of 6,831 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 87,964 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.

Santen Pharmaceutical Trading Up 2.9%

Shares of SNPHY stock traded up $0.34 during trading hours on Thursday, reaching $11.90. 1,062 shares of the stock were exchanged, compared to its average volume of 15,644. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $12.68. The company’s 50-day moving average price is $10.87 and its 200-day moving average price is $10.69. The firm has a market capitalization of $3.84 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.